Abstract
To understand the molecular etiology of osteosarcoma, we isolated and characterized a human osteosarcoma cell line (OS1). OS1 cells have high osteogenic potential in differentiation induction media. Molecular analysis reveals OS1 cells express the pocket protein pRB and the runt-related transcription factor Runx2. Strikingly, Runx2 is expressed at higher levels in OS1 cells than in human fetal osteoblasts. Both pRB and Runx2 have growth suppressive potential in osteoblasts and are key factors controlling competency for osteoblast differentiation. The high levels of Runx2 clearly suggest osteosarcomas may form from committed osteoblasts that have bypassed growth restrictions normally imposed by Runx2. Interestingly, OS1 cells do not exhibit p53 expression and thus lack a functional p53/p21 DNA damage response pathway as has been observed for other osteosarcoma cell types. Absence of this pathway predicts genomic instability and/or vulnerability to secondary mutations that may counteract the anti-proliferative activity of Runx2 that is normally observed in osteoblasts. We conclude OS1 cells provide a valuable cell culture model to examine molecular events that are responsible for the pathologic conversion of phenotypically normal osteoblast precursors into osteosarcoma cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kim KM, Salovaara R, Mecklin JP, Järvinen HJ, Aaltonen LA, Shibata D (2002) PolyA deletions in hereditary nonpolyposis colorectal cancer: mutations before a gatekeeper. Am J Pathol 160:1503–1506
Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, Ghivizzani SC, Ignatova TN, Steindler DA (2005) Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7(11):967–976. doi:10.1593/neo.05394
Blyth K, Cameron ER, Neil JC (2005) The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 5:376–387. doi:10.1038/nrc1607
Kansara M, Thomas DM (2007) Molecular pathogenesis of osteosarcoma. DNA Cell Biol 26:1–18. doi:10.1089/dna.2006.0505
Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB (2005) The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 25:8581–8591. doi:10.1128/MCB.25.19.8581-8591.2005
Thomas DM, Johnson SA, Sims NA, Trivett MK, Slavin JL, Rubin BP, Waring P, McArthur GA, Walkley CR, Holloway AJ, Diyagama D, Grim JE, Clurman BE, Bowtell DD, Lee JS, Gutierrez GM, Piscopo DM, Carty SA, Hinds PW (2004) Terminal osteoblast differentiation, mediated by Runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol 167:925–934. doi:10.1083/jcb.200409187
Thomas DM, Carty SA, Piscopo DM, Lee JS, Wang WF, Forrester WC, Hinds PW (2001) The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell 8:303–316. doi:10.1016/S1097-2765(01)00327-6
Gupta S, Luong MX, Bleuming SA, Miele A, Luong M, Young D, Knudsen ES, Van Wijnen AJ, Stein JL, Stein GS (2003) Tumor suppressor pRB functions as a co-repressor of the CCAAT displacement protein (CDP/cut) to regulate cell cycle controlled histone H4 transcription. J Cell Physiol 196:541–556. doi:10.1002/jcp.10335
Harrington EA, Bruce JL, Harlow E, Dyson N (1998) pRB plays an essential role in cell cycle arrest induced by DNA damage. Proc Natl Acad Sci USA 95:11945–11950. doi:10.1073/pnas.95.20.11945
Mayhew CN, Bosco EE, Fox SR, Okaya T, Tarapore P, Schwemberger SJ, Babcock GF, Lentsch AB, Fukasawa K, Knudsen ES (2005) Liver-specific pRB loss results in ectopic cell cycle entry and aberrant ploidy. Cancer Res 65:4568–4577. doi:10.1158/0008-5472.CAN-04-4221
Fuchs B, Pritchard DJ (2002) Etiology of osteosarcoma. Clin Orthop Relat Res 397:40–52. doi:10.1097/00003086-200204000-00007
Galindo M, Pratap J, Young DW, Hovhannisyan H, Im HJ, Choi JY, Lian JB, Stein JL, Stein GS, van Wijnen AJ (2005) The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J Biol Chem 280:20274–20285. doi:10.1074/jbc.M413665200
Lian JB, Javed A, Zaidi SK, Lengner C, Montecino M, van Wijnen AJ, Stein JL, Stein GS (2004) Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr 14:1–41. doi:10.1615/CritRevEukaryotGeneExpr.v14.i12.10
Pratap J, Galindo M, Zaidi SK, Vradii D, Bhat BM, Robinson JA, Choi JY, Komori T, Stein JL, Lian JB, Stein GS, van Wijnen AJ (2003) Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res 63:5357–5362
Qiao M, Shapiro P, Fosbrink M, Rus H, Kumar R, Passaniti A (2006) Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation. J Biol Chem 281:7118–7128. doi:10.1074/jbc.M508162200
Shen R, Wang X, Drissi H, Liu F, O’Keefe RJ, Chen D (2006) Cyclin D1-cdk4 induces runx2 ubiquitination and degradation. J Biol Chem 281:16347–16353. doi:10.1074/jbc.M603439200
Gartel AL, Feliciano C, Tyner AL (2003) A new method for determining the status of p53 in tumor cell lines of different origin. Oncol Res 13:405–408
Giono LE, Manfredi JJ (2006) The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol 209:13–20. doi:10.1002/jcp.20689
Chen X, Ko LJ, Jayaraman L, Prives C (1996) p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 10:2438–2451. doi:10.1101/gad.10.19.2438
Lengner CJ, Steinman HA, Gagnon J, Smith TW, Henderson JE, Kream BE, Stein GS, Lian JB, Jones SN (2006) Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol 172(6):909–921. doi:10.1083/jcb.200508130
Wang X, Kua HY, Hu Y, Guo K, Zeng Q, Wu Q, Ng HH, Karsenty G, de Crombrugghe B, Yeh J, Li B (2006) p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J Cell Biol 172(1):115–125. doi:10.1083/jcb.200507106
Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB, Yoshida M, Stein GS, Li X (2002) Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol 22:7982–7992. doi:10.1128/MCB.22.22.7982-7992.2002
Acknowledgments
We thank Yoshiaki Ito and Kosei Ito, Institute of Molecular and Cell Biology, Singapore, for providing the Runx2 antibody used in our studies and all the members of the laboratories participating in the Singapore Osteobiology group for stimulating discussions. In particular we thank Ren Xia Fei, Mario Galindo, Nadiya Teplyuk, Kakoli Das, David Leong, Dietmar Hutmacher, Lee Eng Hin, Wong Hee Kit, Jane Lian and Janet Stein for stimulating discussions. This study was co-supported by funding from NIH (grant R01 AR049069 to AvW and grant P01 CA082834 to GS) and Singapore Cancer Syndicate, A*STAR (grants MN-005 and MN-077, to MST).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Each author certifies that his or her institution has approved the human protocol for this investigation that all investigations were conducted in conformity with ethical principles of research, and that informed consent for participation in the study was obtained.
Rights and permissions
About this article
Cite this article
Nathan, S.S., Pereira, B.P., Zhou, Yf. et al. Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Mol Biol Rep 36, 153–158 (2009). https://doi.org/10.1007/s11033-008-9378-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-008-9378-1